Tonix Pharma Appoints New General Counsel and EVP

Tonix Pharma ( (TNXP) ) just unveiled an update.

On May 14, 2025, Tonix Pharmaceuticals announced the appointment of Joseph Hand as General Counsel and Executive Vice President of Operations, effective immediately. This strategic leadership change is expected to impact the company’s operations and potentially strengthen its industry positioning.

The most recent analyst rating on (TNXP) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.

Spark’s Take on TNXP Stock

According to Spark, TipRanks’ AI Analyst, TNXP is a Neutral.

Tonix Pharma’s stock score reflects a company in its growth phase with substantial revenue increases and strategic advancements in product development. However, significant challenges remain in profitability and cash flow sustainability, necessitating ongoing external funding. Positive corporate events provide some optimism, yet weak technical indicators and valuation concerns cap the overall score.

To see Spark’s full report on TNXP stock, click here.

More about Tonix Pharma

Tonix Pharmaceuticals Holding Corp. operates in the pharmaceutical industry, focusing on product development, clinical trials, and regulatory timelines to enhance its market opportunity and competitive position.

Average Trading Volume: 1,306,191

Technical Sentiment Signal: Sell

Current Market Cap: $132M

See more insights into TNXP stock on TipRanks’ Stock Analysis page.